FI118536B - Monoklonal anti-alfa V-integrinantikropp - Google Patents
Monoklonal anti-alfa V-integrinantikropp Download PDFInfo
- Publication number
- FI118536B FI118536B FI956112A FI956112A FI118536B FI 118536 B FI118536 B FI 118536B FI 956112 A FI956112 A FI 956112A FI 956112 A FI956112 A FI 956112A FI 118536 B FI118536 B FI 118536B
- Authority
- FI
- Finland
- Prior art keywords
- cell
- cells
- integrin
- antibody
- monoclonal antibody
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/36—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against blood coagulation factors
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2839—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the integrin superfamily
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12P—FERMENTATION OR ENZYME-USING PROCESSES TO SYNTHESISE A DESIRED CHEMICAL COMPOUND OR COMPOSITION OR TO SEPARATE OPTICAL ISOMERS FROM A RACEMIC MIXTURE
- C12P21/00—Preparation of peptides or proteins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
Landscapes
- Chemical & Material Sciences (AREA)
- Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Immunology (AREA)
- Medicinal Chemistry (AREA)
- Genetics & Genomics (AREA)
- Molecular Biology (AREA)
- Biochemistry (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Biophysics (AREA)
- Engineering & Computer Science (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Zoology (AREA)
- Wood Science & Technology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pharmacology & Pharmacy (AREA)
- Hematology (AREA)
- Public Health (AREA)
- Biotechnology (AREA)
- Microbiology (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Engineering & Computer Science (AREA)
- Peptides Or Proteins (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
Claims (20)
1. Monoklonal antikropp, kännetecknad av att den omfattar arainosyrasekvenserna av framework-regionerna 5 (FR) och complementarity determing-regionerna (CDR) i den lätta kedjan med sekvensnr 1 och den tunga kedjan med se-kvensnr 9 .
2. Monoklonal antikropp enligt patentkrav 1, kännetecknad av att den uppvisar följande egenskaper: 10 den reagerar endast med aV-kedjan av mänskliga aV- integriner, den blockerar fästandet av den aV-integrinbärande cellen till inte-grinsubstratet, den utlöser reversering av etablerad cellmatrixin-15 teraktion som aV-integriner förorsakat, den blockerar tumörutveckling och den visar inte cytotoxisk aktivitet.
3. Monoklonal antikropp enligt patentkrav 1 eller 2, kännetecknad av att integrinsubstratet är vitronek- 20 tin, fibrinogen eller fibronektin.
4. Monoklonal antikropp enligt patentkraven 1 - 3, • · ϊ.*·· kännetecknad av att tumören, vars cellväxt blockeras, är melanom.
*:··· 5. Monoklonalt ant ikropps fragment, som omfattar . .*. 25 aminosyrasekvenserna enligt patentkrav 1 och som uppvisar ··♦ : .·. de i patentkraven 2-4 beskrivna egenskaperna, känne- [···[ tecknat av att nämnda fragment är bivalent. • · ·
6. Hybridomcellinje med benämningen 272-17E6 och „ deponerad med ätkomstnummer DSM ACC2160, kännetecknad 30 av att den är kapabel att producera en monoklonal anti-kropp enligt patentkraven 1 - 4.
7. Monoklonal antikropp enligt patentkrav 1, kän- * · · ....: netecknad av att den kan erhällas frän hybridomcellin- • jen DSM ACC2160. I» · J • · ; ·* 35
8. Aminosyrasekvens, kännetecknad av att den • · · *...* omfattar sekvensen enligt sekvens nr 1. 118536 71
9. Aminosyrasekvens, kännetecknad av att den omfattar sekvensen enligt sekvens nr 9.
10. Aminosyrasekvens enligt patentkrav 8, kännetecknad av att den börjar frän position 21.
11. Aminosyrasekvens enligt patentkrav 9, känne tecknad av att den börjar frän position 20.
12. DNA-sekvens, kännetecknad av att den om-fattar DNA-sekvensen enligt sekvens nr 1 som kodar för FR-regionerna och CDR-regionerna i den Iätta kedjan i den valo riabla regionen av en monoklonal antikropp som uppvisar de i patentkrav 2 definierade egenskaperna.
13. DNA-sekvens, kännetecknad av att den om-fattar DNA-sekvensen enligt sekvens nr 9 som kodar för FR-regionerna och CDR-regionerna i den tunga kedjan i den va- 15 riabla regionen av en monoklonal antikropp som uppvisar de i patentkrav 2 definierade egenskaperna.
14. DNA-sekvens enligt patentkrav 12, kännetecknad av att den omf attar ledarsekvensen som är angi-ven i sekvens nr l.
15. DNA-sekvens enligt patentkrav 13, känne tecknad av att den omf attar ledarsekvensen som är angi-*,**: ven i sekvens nr 9.
*·’* 16. Farmaceutisk komposition, kännetecknad av ·!**: att den omfattar en monoklonal antikropp enligt nägot av : 25 patentkraven 1-5 eller 7, och en farmaceutiskt godtagbar III ϊ .*. bärare. • * · «·· «
17. Förfarande för framställning av en monoklonal » f · antikropp enligt nägot av patentkraven 1-5 eller 7 genom .. att utföra följande steg: • · · *... 30 (i) en mus immuniseras med renat θνβ3-integrin • · *·;·* (ii) hybridomceller framställs • · · ϊ>>#: (iii) kloner väljs, vilkas supernatanter visar po- ·:··; sitiva resultat och ett reaktionsmönster som överensstämmer med deras igenkänning av aV-integrinkedjän * S • · ··« • · * · *·· 118536 72 (iv) kloner väljs, vilkas supernatanter blockerar fästandet av celler som uttrycker aV-kedjans integrin till matrixprotein (v) kloner väljs, vilkas supernatanter blockerar 5 tumörutveckling (vi) kloner väljs, vilkas supernatanter inte visar cytotoxitet (vii) kloner väljs, vilkas supernatanter utlöser reversering av etablerad integrinmedierad cellmatrixinte- 10 raktion (viii) en specifik cellinje produceras och (ix) den raonoklonala antikroppen isoleras frän nämnda cellinje.
18. Användning av en monoklonal antikropp enligt 15 nägot av patentkraven 1-5 eller 7 för framställning av ett läkemedel som är riktat mot tumörer.
19. Användning enligt patentkrav 18, varvid tumö-ren är melanom.
20. Användning av en monoklonal antikropp enligt 20 nägot av patentkraven 1-5 eller 7 för framställning av en diagnostisk förening för lokalisering och bestämning av • · ·,**: tumörväxt. • ••f • · • · • · · • · · • Il • · • · · • · « ··· · • ·· • · · * * · ·« • · • ·· ··· • · • · ·«· ·«· · • · ··· ' · · ·· Φ • · · • · m « «·· • · • · • ft
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP94120165 | 1994-12-20 | ||
| EP94120165 | 1994-12-20 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| FI956112A0 FI956112A0 (sv) | 1995-12-19 |
| FI956112A FI956112A (sv) | 1996-06-21 |
| FI118536B true FI118536B (sv) | 2007-12-14 |
Family
ID=8216547
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| FI956112A FI118536B (sv) | 1994-12-20 | 1995-12-19 | Monoklonal anti-alfa V-integrinantikropp |
Country Status (26)
| Country | Link |
|---|---|
| US (1) | US5985278A (sv) |
| EP (1) | EP0719859B1 (sv) |
| JP (1) | JP3898245B2 (sv) |
| KR (1) | KR100450368B1 (sv) |
| CN (1) | CN1117763C (sv) |
| AR (1) | AR001778A1 (sv) |
| AT (1) | ATE244306T1 (sv) |
| AU (1) | AU710234B2 (sv) |
| BR (1) | BR9505980B1 (sv) |
| CA (1) | CA2165573C (sv) |
| CO (1) | CO4480042A1 (sv) |
| CZ (1) | CZ290477B6 (sv) |
| DE (1) | DE69531187T2 (sv) |
| DK (1) | DK0719859T3 (sv) |
| ES (1) | ES2202336T3 (sv) |
| FI (1) | FI118536B (sv) |
| HU (1) | HU221061B1 (sv) |
| NO (1) | NO321186B1 (sv) |
| PL (1) | PL182961B1 (sv) |
| PT (1) | PT719859E (sv) |
| RU (1) | RU2205223C2 (sv) |
| SI (1) | SI0719859T1 (sv) |
| SK (1) | SK284932B6 (sv) |
| TR (1) | TR199501614A2 (sv) |
| UA (1) | UA40621C2 (sv) |
| ZA (1) | ZA9510806B (sv) |
Families Citing this family (62)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU4134497A (en) * | 1996-09-03 | 1998-03-26 | Chugai Seiyaku Kabushiki Kaisha | Anti-integrin alpha3 antibody complexes |
| ES2321991T3 (es) * | 1996-12-09 | 2009-06-15 | Merck Patent Gmbh | Receptor de adhesion alfavbet3 recombinante soluble. |
| EP0996460B1 (en) * | 1997-08-08 | 2005-01-12 | The Regents of the University of California | Treatment of kidney fibrosis with antibodies against integrin alpha-v-beta 6 |
| ID27810A (id) * | 1998-01-23 | 2001-04-26 | Merck Patent Gmbh | Antibodi menoclonal anti v-integrin dan kegunaan untuk mencegah penambahan v 6-integrin untuk fibronectin |
| US6160099A (en) | 1998-11-24 | 2000-12-12 | Jonak; Zdenka Ludmila | Anti-human αv β3 and αv β5 antibodies |
| US6521593B1 (en) * | 1999-02-01 | 2003-02-18 | Childrens Hospital Los Angeles | Methods for inhibiting brain tumor growth |
| US7153944B2 (en) * | 2000-07-31 | 2006-12-26 | The General Hospital Corporation | High affinity integrin polypeptides and uses thereof |
| US7064180B2 (en) | 2000-07-31 | 2006-06-20 | The General Hospital Corporation | High affinity integrin polypeptides and uses thereof |
| US7323552B2 (en) * | 2000-07-31 | 2008-01-29 | The General Hospital Corporation | Variant integrin polypeptides and uses thereof |
| US7163681B2 (en) | 2000-08-07 | 2007-01-16 | Centocor, Inc. | Anti-integrin antibodies, compositions, methods and uses |
| US7288390B2 (en) | 2000-08-07 | 2007-10-30 | Centocor, Inc. | Anti-dual integrin antibodies, compositions, methods and uses |
| MXPA03007878A (es) * | 2001-03-02 | 2004-07-08 | Medimmune Inc | Metodos de prevencion o tratamiento de alteraciones inflamatorias o autoinmunes mediante la administracion de los antagonistas alfav, beta3 de integrina. |
| DK1381384T3 (da) | 2001-04-24 | 2011-07-25 | Merck Patent Gmbh | Kombinationsterapi under anvendelse af anti-angiogene midler og TNFalfa |
| US7829087B2 (en) * | 2001-07-09 | 2010-11-09 | Elan Pharmaceuticals, Inc. | Methods of treating cognitive impairment |
| EP1414491A4 (en) | 2001-07-09 | 2005-07-06 | Elan Pharm Inc | METHOD OF INHIBITING THE TOXICITY OF AMYLOID |
| CA2478317A1 (en) * | 2002-03-04 | 2003-09-18 | Medimmune, Inc. | Methods of preventing or treating disorders by administering an integrin .alpha.v.beta.3 antagonist in combination with an hmg-coa reductase inhibitor or a bisphosphonate |
| CA2478239A1 (en) * | 2002-03-04 | 2003-09-18 | Medimmune, Inc. | The prevention or treatment of cancer using integrin alphavbeta3 antagonists in combination with other agents |
| CN100509851C (zh) * | 2002-03-13 | 2009-07-08 | 拜奥根Idec马萨诸塞公司 | 抗αvβ6抗体 |
| EP2287198A3 (en) * | 2002-03-13 | 2011-05-25 | Biogen Idec MA Inc. | Anti-alpha V beta 6 antibodies |
| AU2003230929A1 (en) * | 2002-04-12 | 2003-10-27 | Raven Biotechnologies, Inc. | Antibodies that bind to integrin alpha-v-beta-6 and methods of use thereof |
| JP2005535572A (ja) | 2002-04-12 | 2005-11-24 | メディミューン，インコーポレーテッド | 組換え抗インターロイキン−９抗体 |
| US20040176272A1 (en) * | 2003-01-30 | 2004-09-09 | Medimmune, Inc. | Uses of integrin alphavbeta3 antagonists |
| AU2004229501B2 (en) | 2003-04-11 | 2011-08-18 | Medimmune, Llc | Recombinant IL-9 antibodies and uses thereof |
| US7351739B2 (en) * | 2004-04-30 | 2008-04-01 | Wellgen, Inc. | Bioactive compounds and methods of uses thereof |
| WO2006047639A2 (en) | 2004-10-27 | 2006-05-04 | Medimmune, Inc. | Modulation of antibody specificity by tailoring the affinity to cognate antigens |
| CN104072614B (zh) | 2005-07-08 | 2017-04-26 | 生物基因Ma公司 | 抗-αvβ6 抗体及其用途 |
| AR060040A1 (es) * | 2006-03-21 | 2008-05-21 | Genentech Inc | Antagonistas de vefg y de alfa5 beta 1 |
| CA2662905A1 (en) | 2006-07-10 | 2008-01-17 | Biogen Idec Ma Inc. | Compositions and methods for inhibiting growth of smad4-deficient cancers |
| EP2043603A4 (en) | 2006-07-11 | 2010-10-27 | Arubor Corp | PREVENTION AND THERAPY OF RHINOSINUSITIS WITH PROINFLAMMATORY CYTOKINHERMERS |
| DK2068889T3 (da) | 2006-08-10 | 2020-02-03 | Roy C Levitt | Anakinra til anvendelse i behandling af bronchiolitis obliterans syndrom |
| WO2008141276A1 (en) * | 2007-05-11 | 2008-11-20 | Centocor, Inc. | Anti-alpha-v immunoliposome composition, methods and uses |
| US20090175784A1 (en) | 2007-05-11 | 2009-07-09 | Joshua Goldstein | Anti-Alpha V Immunoliposome Composition, Methods, and Uses |
| PT2167128E (pt) * | 2007-07-17 | 2013-01-24 | Merck Patent Gmbh | Anticorpos híbridos anti-integrina alfa v manipulados |
| PE20091029A1 (es) * | 2007-09-26 | 2009-08-19 | Genentech Inc | Anticuerpos anti-alfa 5 beta 1 |
| CA2747937C (en) | 2008-12-23 | 2019-02-26 | Merck Patent Gmbh | Biomarkers for inhibitors with anti-angiogenic activity |
| MY173526A (en) | 2009-03-25 | 2020-01-31 | Genentech Inc | Novel anti-?5?1 antibodies and uses thereof |
| MX2012005423A (es) | 2009-11-13 | 2012-06-14 | Merck Patent Gmbh | Anticuerpos anti-integrina unidos a nanoparticulas cargadas con agentes quimioterapeuticos. |
| EP4219560A3 (en) * | 2010-02-18 | 2023-08-23 | The Regents of The University of California | Integrin alpha v beta 8 neutralizing antibody |
| EP2608804A4 (en) * | 2010-08-27 | 2015-03-11 | Univ Miami | TREATMENT OF RENAL DISEASES |
| KR101972533B1 (ko) | 2011-02-11 | 2019-08-26 | 메르크 파텐트 게엠베하 | 전립선암 치료용 항-알파-ｖ 인테그린 항체 |
| WO2012143499A2 (de) | 2011-04-21 | 2012-10-26 | Bayer Intellectual Property Gmbh | Neue binder-wirkstoff konjugate (adcs) und ihre verwendung |
| US9492569B2 (en) * | 2011-08-17 | 2016-11-15 | The Regents Of The University Of California | Antibodies that bind integrin alpha-V beta-8 |
| US10035860B2 (en) | 2013-03-15 | 2018-07-31 | Biogen Ma Inc. | Anti-alpha V beta 6 antibodies and uses thereof |
| WO2014144466A1 (en) | 2013-03-15 | 2014-09-18 | Biogen Idec Ma Inc. | Anti-alpha v beta 6 antibodies and uses thereof |
| RU2698697C2 (ru) | 2013-12-23 | 2019-08-29 | Байер Фарма Акциенгезельшафт | Конъюгаты связующего (ADC) с ингибиторами KSP |
| CN106714835A (zh) | 2014-09-17 | 2017-05-24 | 默克专利股份公司 | 治疗骨转移疾病的方法、其药物以及预测治疗骨转移疾病的临床结果的方法 |
| EP3193927B1 (en) | 2014-09-17 | 2020-11-25 | Merck Patent GmbH | A method of treating solid cancers and/or metastases thereof, medicaments therefore, and a method of predicting the clinical outcome of treating solid cancers and/or metastases thereof |
| PE20180610A1 (es) | 2015-06-22 | 2018-04-09 | Bayer Pharma AG | CONJUGADOS DE LIGADOR-PRINCIPIO ACTIVO (ADCs) Y CONJUGADOS DE LIGADOR-PROFARMACO (APDCs) CON GRUPOS ENZIMATICAMENTE ESCINDIBLES |
| MX2017017138A (es) | 2015-06-23 | 2018-04-30 | Bayer Pharma AG | Conjugados homogeneos especificos de sitio con inhibidores de ksp. |
| WO2017060322A2 (en) | 2015-10-10 | 2017-04-13 | Bayer Pharma Aktiengesellschaft | Ptefb-inhibitor-adc |
| US20190144547A1 (en) | 2015-11-23 | 2019-05-16 | Merck Patent Gmbh | Anti-alpha-v integrin antibody for the treatment of fibrosis and/or fibrotic disorders |
| JP7251981B2 (ja) | 2016-03-24 | 2023-04-04 | バイエル ファーマ アクチエンゲゼルシャフト | 酵素開裂基を有する細胞毒性活性剤のプロドラッグ |
| EP3919518A1 (en) | 2016-06-15 | 2021-12-08 | Bayer Pharma Aktiengesellschaft | Specific antibody-drug-conjugates (adcs) with ksp inhibitors and anti-cd123-antibodies |
| US20190242908A1 (en) | 2016-09-08 | 2019-08-08 | INSERM (Institut National de la Santé et de la Recherche Médicale) | Methods for diagnosing and treating nephrotic syndrome |
| IL310558A (en) | 2016-12-21 | 2024-03-01 | Bayer Pharma AG | Drug-antibody conjugates with enzymatically cleavable groups |
| EP3558387B1 (de) | 2016-12-21 | 2021-10-20 | Bayer Pharma Aktiengesellschaft | Spezifische antikörper-wirkstoff-konjugate (adcs) mit ksp-inhibitoren |
| KR20190099250A (ko) | 2016-12-21 | 2019-08-26 | 바이엘 악티엔게젤샤프트 | 효소적으로 절단가능한 기를 갖는 세포독성 활성제의 전구약물 |
| KR101961715B1 (ko) | 2018-07-18 | 2019-03-25 | (주) 삼진정밀 | 고효율 수처리장치 |
| US20200121788A1 (en) | 2018-10-19 | 2020-04-23 | Merck Patent Gmbh | Abituzumab for the treatment of colorectal cancer |
| KR101999620B1 (ko) | 2019-03-26 | 2019-07-12 | 조용진 | 부상슬러지 및 침전슬러지의 동시처리장치 |
| EA202192400A1 (ru) * | 2019-04-08 | 2022-01-25 | Биоген Ма Инк. | Антитела против интегрина и их применение |
| CN117143241B (zh) * | 2023-10-26 | 2024-02-23 | 迈威(上海)生物科技股份有限公司 | 与人整合素蛋白itgav/itgb8特异性结合的单克隆抗体 |
Family Cites Families (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP0633945B1 (en) * | 1992-04-03 | 1998-12-30 | Genentech, Inc. | ANTIBODIES TO ALPHAvBETA3 INTEGRIN |
| US5753230A (en) * | 1994-03-18 | 1998-05-19 | The Scripps Research Institute | Methods and compositions useful for inhibition of angiogenesis |
-
1995
- 1995-12-06 DE DE69531187T patent/DE69531187T2/de not_active Expired - Lifetime
- 1995-12-06 SI SI9530683T patent/SI0719859T1/xx unknown
- 1995-12-06 AT AT95119233T patent/ATE244306T1/de active
- 1995-12-06 DK DK95119233T patent/DK0719859T3/da active
- 1995-12-06 PT PT95119233T patent/PT719859E/pt unknown
- 1995-12-06 ES ES95119233T patent/ES2202336T3/es not_active Expired - Lifetime
- 1995-12-06 EP EP95119233A patent/EP0719859B1/en not_active Expired - Lifetime
- 1995-12-13 AU AU40421/95A patent/AU710234B2/en not_active Ceased
- 1995-12-13 CZ CZ19953288A patent/CZ290477B6/cs not_active IP Right Cessation
- 1995-12-18 JP JP32887795A patent/JP3898245B2/ja not_active Expired - Fee Related
- 1995-12-18 CA CA2165573A patent/CA2165573C/en not_active Expired - Fee Related
- 1995-12-19 HU HU9503638A patent/HU221061B1/hu not_active IP Right Cessation
- 1995-12-19 FI FI956112A patent/FI118536B/sv not_active IP Right Cessation
- 1995-12-19 ZA ZA9510806A patent/ZA9510806B/xx unknown
- 1995-12-19 US US08/574,699 patent/US5985278A/en not_active Expired - Lifetime
- 1995-12-19 NO NO19955167A patent/NO321186B1/no not_active IP Right Cessation
- 1995-12-19 PL PL95311926A patent/PL182961B1/pl unknown
- 1995-12-19 RU RU95121105/13A patent/RU2205223C2/ru not_active IP Right Cessation
- 1995-12-19 SK SK1592-95A patent/SK284932B6/sk not_active IP Right Cessation
- 1995-12-19 UA UA95125376A patent/UA40621C2/uk unknown
- 1995-12-19 CN CN95120901A patent/CN1117763C/zh not_active Expired - Fee Related
- 1995-12-20 BR BRPI9505980-6A patent/BR9505980B1/pt not_active IP Right Cessation
- 1995-12-20 TR TR95/01614A patent/TR199501614A2/xx unknown
- 1995-12-20 CO CO95060553A patent/CO4480042A1/es unknown
- 1995-12-20 KR KR1019950052440A patent/KR100450368B1/ko not_active IP Right Cessation
- 1995-12-20 AR AR33473095A patent/AR001778A1/es active IP Right Grant
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| FI118536B (sv) | Monoklonal anti-alfa V-integrinantikropp | |
| CN108503708B (zh) | 抗人cd47抗体及其用途 | |
| TWI469792B (zh) | 新穎之抗ｃｘｃｒ４抗體及其於治療癌症之用途 | |
| CN110352200A (zh) | 抗具有Ig和ITIM结构域的T细胞免疫受体(TIGIT)的抗体及其应用 | |
| US7271245B2 (en) | Methods and compositions for inhibition of metastasis | |
| AU2007324509B2 (en) | Novel antiproliferation antibodies | |
| CN101432305A (zh) | 运铁蛋白受体抗体 | |
| CN101282993A (zh) | 针对cd20的抗体和其用途 | |
| CA2619654A1 (en) | Combination therapies for inhibiting integrin-extracellular matrix interactions | |
| CA2554537A1 (en) | Method and composition for angiogenesis inhibition | |
| KR20110010708A (ko) | 암을 치료하는데 사용되는 새로운 항체들 | |
| KR20010034327A (ko) | 모노클로날 항체 항 αν-인테그린, 및 피브로넥틴에 대한ανβ6-인테그린 부착을 억제하기 위한 그의 용도 | |
| WO2004002528A1 (en) | Compositions and methods for therapeutic treatment | |
| CN113912721A (zh) | 一种抗人cd47的单克隆抗体及其应用 | |
| MXPA00007178A (en) | MONOCLONAL ANTIBODY ANTI&agr;v-INTEGRIN AND ITS USE TO INHIBIT&agr;v&bgr;6-INTEGRIN ATTACHMENT TO FIBRONECTIN | |
| CZ20002659A3 (cs) | Monoklonální protilátka anti av-integrin a její použití k inhibicí vazby avbetaó-integrinu na fibronektin |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FG | Patent granted |
Ref document number: 118536 Country of ref document: FI |
|
| MM | Patent lapsed |